GPT and Hepatitis: A higher risk of hepatitis flares in patients after the discontinuation of TDF therapy was consistently observed in various subgroups, including patients with an off-therapy HBV DNA change less than 1 log10 IU per month, qHBsAg at EOT ≥ 150 IU/mL, consolidation therapy less than 60 months, previous antiviral therapy more than 36 months, and an ALT higher than the AASLD criteria threshold, regardless of age (<65 or ≥65) or sex.